Newstral
Article
Mmarketwatch.com on 2017-05-17 15:55
Meridian Bioscience stock plummets after FDA warns subsidiary's lead tests may be inaccurate
Related news
- FDA targets inaccurate medical tests, citing dangers and costsseattletimes.com
- FDA Warns Abbott Coronavirus Tests Could Be InaccurateForbes
- FDA pushed through scores of inaccurate antibody tests without agency reviewPOLITICO
- Small Cap Meridian Bioscience Tests Well For Value And DividendsForbes
- CMeridian Bioscience sued over stock drop, diligence in buying lead blood-test firmcincinnati.com
- Some herbal supplements' labels inaccurate, tests findThe Columbian
- FDA releases warning on 'fever cameras,' calling some inaccurateWRAL
- FCOVID-19 antigen tests recalled over potential for inaccurate resultsfoxbusiness.com
- Parents beware: Silicon Valley hypes inaccurate prenatal blood testsjdsupra.com
- Blood tests significantly underestimated lead levels, FDA and CDC warnWashington Post
- MCatalyst Pharma stock plummets after FDA approves competitor's drugmarketwatch.com
- FDA Warns Pfizer's Meridian Unit on EpiPen Oversight, Quality Issueswsj.com
- MSanthera plummets 35% after FDA denies accelerated DMD drug approvalmarketwatch.com
- Acer Therapeutics stock plummets 80 percent on FDA rejectionbizjournals.com
- MDon’t use this COVID rapid antigen test, FDA warns. It could cause inaccurate resultsmiamiherald.com
- MMeridian Bioscience stock drops 9% on first-quarter earnings and revenue misses, guidance cuts and cash dividend reductionmarketwatch.com
- FDA proposes new regulation of lab testsjournalrecord.com
- FDA finalizes guidances for NGS-based testsjdsupra.com
- FDA Signals Easier Rule on Genetic Testswsj.com
- FDA relents on home genetic teststriblive.com